grant
SLC6A14 as a unique drug target to treat pancreatic cancer
Organization TEXAS TECH UNIVERSITY HEALTH SCIS CENTERLocation LUBBOCK, UNITED STATESPosted 12 May 2023Deadline 30 Apr 2028
NIHUS FederalResearch GrantFY2026Amino Acid ChannelAmino Acid Transport SystemsAmino Acid TransporterAmino AcidsAreaAspartateAttenuatedAutophagocytosisBiochemicalBiologicalCancersCarbonCell BodyCell Communication and SignalingCell LineCell SignalingCellLineCellsCombined Modality TherapyCompensationDNADeoxyribonucleic AcidDevelopmentDrug CombinationsDrug TargetingEssential Amino AcidsGeneralized GrowthGeneticGenetic ModelsGlutamatesGlutathioneGoalsGrowthHeterograftHeterologous TransplantationHumanHydroxychlorochinHydroxychloroquineIn VitroIntracellular Communication and SignalingKPC genetically-engineered mouseKPC modelKPC mouseKPC murineKRAS(G12D)KRASG12DL-AspartateL-GlutamateL-TryptophanLSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-CreLSL-KrasG12D/+;LSL-p53R172H/+;Pdx-1-CreLaboratoriesLesionLevotryptophanMaintenanceMalignant CellMalignant NeoplasmsMalignant Pancreatic NeoplasmMalignant TumorMalignant neoplasm of pancreasModelingModern ManMolecularMonitorMultimodal TherapyMultimodal TreatmentNon-Essential Amino AcidNonessential Amino AcidNutrientNutritionOxidative StressOxychlorochinOxychloroquinePDA modelPDAC ModelPDAC cancer cellPDAC cellPanINPancreasPancreas CancerPancreas Ductal AdenocarcinomaPancreas NeoplasmsPancreas TumorPancreaticPancreatic CancerPancreatic Duct DysplasiaPancreatic Ductal AdenocarcinomaPancreatic Ductal DysplasiaPancreatic Intraepithelial NeoplasiaPancreatic TumorProcessProteomicsPublishingSamplingSignal PathwaySignal TransductionSignal Transduction SystemsSignalingStarvationStrains Cell LinesStressTestingTissue GrowthTissue SampleTreatment EfficacyTryptophanTumor TissueUpregulationXenograftXenograft procedureXenotransplantationaminoacidanti-cancerattenuateattenuatesattenuationautophagybiologicbiological signal transductioncancer cellcombination therapycombined modality treatmentcombined treatmentcultured cell linedeprivationdevelopmentalefficacy testingexperimentexperimental researchexperimental studyexperimentsgamma-L-Glu-L-Cys-Glygamma-L-Glutamyl-L-Cysteinylglycineglutamatergichistone methylationimplantationimprovedin vivo Modelinhibition of autophagyinnovateinnovationinnovativeinterestintervention efficacyknock-downknockdownmalignancymetabolism measurementmetabolomicsmetabonomicsmolecular biomarkermolecular markermouse modelmulti-modal therapymulti-modal treatmentmurine modelneoplasm/cancerneoplasticnovelontogenypancreas duct dysplasiapancreas ductal dysplasiapancreatic ductal adenocarcinoma cellpancreatic ductal adenocarcinoma modelpancreatic malignancypancreatic neoplasiapancreatic neoplasmpharmacologicresponsetargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic efficacytherapeutic outcometherapy efficacytherapy outcometreatment strategyxeno-transplantxeno-transplantation
Sign up free to applyApply link ยท pipeline ยท email alerts
or
โ or โGet email alerts for similar roles
Description preview
Pancreatic ductal adenocarcinoma (PDAC) is lethal. Our laboratory has identified SLC6A14 to be highly
upregulated in PDAC. SLC6A14 is a broad selective amino acid transporter with the ability to transport both
essential and non-essential amino acids, which includes amino acids for mTORC1 activation, one-carbon
moiety for DNA/histone methylation,โฆ
๐
Start 7-day free trial โ $29.99/mo โFull details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link โ plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more โ with email alerts and pipeline tracking.
$29.99 / month
- ๐Email alerts for new matching tenders
- ๐๏ธTrack tenders in your pipeline
- ๐ฐFilter by contract value
- ๐ฅExport results to CSV
- ๐Save searches with one click